Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111852 · ClinicalTrials.gov registry record · Phase 3
Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS-2)
A Phase 3 study of Stroke, Acute, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 193
- Enrollment target
- 20
- Study locations
NCT00111852 is a Phase 3 study of Stroke, Acute that has completed, run by Forest Laboratories. The registered enrollment target is 193 participants, below the 622-participant average among 25 other Stroke, Acute trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT00111852, a Phase 3 study of Stroke, Acute, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 193 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate desmoteplase (which is a manufactured protein derived from the saliva of the vampire bat) in dissolving clots that are blocking the flow of blood through one (or more) of the blood vessels supplying the brain, thereby reopening the blocked blood vessel and allowing blood to flow again in individuals suffering from ischemic stroke.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Desmoteplase
Study Locations (20)
Florida
- Brain Matters, Inc. - Delray Beach
- Melbourne Internal Medicine Associates (MIMA) - Melbourne
- Holmes Regional Medical Center - Melbourne
- Tampa General Hospital - Tampa
Massachusetts
- Massachusetts General Hospital - Boston
- Boston University Medical Center - Boston
- Beth Israel Deaconess Medical Center (BIDMC) - Boston
Indiana
- Parkview Hospital - Fort Wayne
- Indiana Neuroscience Institute - Indianapolis
Kentucky
- Jewish Hospital Healthcare Services, Inc. - Louisville
- University of Louisville Hospital - Louisville
Ohio
- The Cleveland Clinic Foundation - Cleveland
- The Ohio State University Medical Center - Columbus
Alabama
- Alabama Neurological Institute, Dept. of Neurology - Birmingham
California
- University of California Los Angeles Medical Center - Los Angeles
Illinois
- Loyola University Medical Center - Maywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2005-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00111852
The ClinicalTrials.gov registry entry for NCT00111852 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 193 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 622-participant average among 25 other Stroke, Acute trials with a reported enrollment target (69% lower). The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stroke, Acute appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00111852 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Massachusetts, Indiana.
Frequently Asked Questions
What is clinical trial NCT00111852 about?
NCT00111852 is a clinical study titled "Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS-2)". The purpose of this study is to evaluate desmoteplase (which is a manufactured protein derived from the saliva of the vampire bat) in dissolving clots that are blocking the flow of blood through one (or more) of the blood vessels supplying the brain, thereby reopening the blocked blood vessel and al...
What is the current status of trial NCT00111852?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 193 participants. The study started on 2005-04.
What conditions does trial NCT00111852 study?
This clinical trial studies the following conditions: Stroke, Acute.
What interventions are being tested in trial NCT00111852?
The interventions under investigation include: Placebo (DRUG), Desmoteplase (DRUG).
Who is sponsoring clinical trial NCT00111852?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00111852 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke, Acute
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Somatic Dysfunction in Patients With Acute Cerebrovascular Disease
RECRUITING
-
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
RECRUITING · NA
-
Focused Intensive Repeated Stepping During Inpatient Rehabilitation Poststroke - A Quality Improvement Project
RECRUITING
-
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
RECRUITING · NA
-
Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe
RECRUITING · NA
-
Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.